Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MVRBF's Cash to Debt is ranked higher than
85% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. MVRBF: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MVRBF' s 10-Year Cash to Debt Range
Min: 10.06  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.86
MVRBF's Equity to Asset is ranked higher than
74% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. MVRBF: 0.86 )
Ranked among companies with meaningful Equity to Asset only.
MVRBF' s 10-Year Equity to Asset Range
Min: 0.75  Med: 0.84 Max: 0.92
Current: 0.86
0.75
0.92
Interest Coverage No Debt
MVRBF's Interest Coverage is ranked higher than
72% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MVRBF: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MVRBF' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 8
Z-Score: 10.30
WACC vs ROIC
11.62%
117.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 66.28
MVRBF's Operating margin (%) is ranked higher than
98% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. MVRBF: 66.28 )
Ranked among companies with meaningful Operating margin (%) only.
MVRBF' s 10-Year Operating margin (%) Range
Min: -544.37  Med: -107.64 Max: 67.27
Current: 66.28
-544.37
67.27
Net-margin (%) 51.59
MVRBF's Net-margin (%) is ranked higher than
95% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. MVRBF: 51.59 )
Ranked among companies with meaningful Net-margin (%) only.
MVRBF' s 10-Year Net-margin (%) Range
Min: -527.08  Med: -98.51 Max: 64.11
Current: 51.59
-527.08
64.11
ROE (%) 58.15
MVRBF's ROE (%) is ranked higher than
98% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. MVRBF: 58.15 )
Ranked among companies with meaningful ROE (%) only.
MVRBF' s 10-Year ROE (%) Range
Min: -69.41  Med: -17.56 Max: 79.91
Current: 58.15
-69.41
79.91
ROA (%) 52.20
MVRBF's ROA (%) is ranked higher than
99% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. MVRBF: 52.20 )
Ranked among companies with meaningful ROA (%) only.
MVRBF' s 10-Year ROA (%) Range
Min: -52.66  Med: -18.01 Max: 71.26
Current: 52.2
-52.66
71.26
ROC (Joel Greenblatt) (%) 413.76
MVRBF's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. MVRBF: 413.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MVRBF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -518.61  Med: -21.93 Max: 1012.27
Current: 413.76
-518.61
1012.27
Revenue Growth (3Y)(%) 34.30
MVRBF's Revenue Growth (3Y)(%) is ranked higher than
85% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. MVRBF: 34.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MVRBF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -50.3  Med: -15.60 Max: 85.9
Current: 34.3
-50.3
85.9
EBITDA Growth (3Y)(%) 105.30
MVRBF's EBITDA Growth (3Y)(%) is ranked higher than
97% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. MVRBF: 105.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MVRBF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -19.50 Max: 105.3
Current: 105.3
0
105.3
EPS Growth (3Y)(%) 111.40
MVRBF's EPS Growth (3Y)(%) is ranked higher than
98% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. MVRBF: 111.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MVRBF' s 10-Year EPS Growth (3Y)(%) Range
Min: -42.5  Med: -0.40 Max: 111.4
Current: 111.4
-42.5
111.4
» MVRBF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MVRBF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 3.10
MVRBF's P/E(ttm) is ranked higher than
95% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. MVRBF: 3.10 )
Ranked among companies with meaningful P/E(ttm) only.
MVRBF' s 10-Year P/E(ttm) Range
Min: 2.48  Med: 15.66 Max: 76.94
Current: 3.1
2.48
76.94
PE(NRI) 3.10
MVRBF's PE(NRI) is ranked higher than
96% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. MVRBF: 3.10 )
Ranked among companies with meaningful PE(NRI) only.
MVRBF' s 10-Year PE(NRI) Range
Min: 2.48  Med: 15.83 Max: 238.54
Current: 3.1
2.48
238.54
P/B 1.70
MVRBF's P/B is ranked higher than
85% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. MVRBF: 1.70 )
Ranked among companies with meaningful P/B only.
MVRBF' s 10-Year P/B Range
Min: 1.35  Med: 2.48 Max: 14.04
Current: 1.7
1.35
14.04
P/S 1.59
MVRBF's P/S is ranked higher than
92% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. MVRBF: 1.59 )
Ranked among companies with meaningful P/S only.
MVRBF' s 10-Year P/S Range
Min: 1.27  Med: 6.32 Max: 83.08
Current: 1.59
1.27
83.08
PFCF 2.24
MVRBF's PFCF is ranked higher than
99% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 45.01 vs. MVRBF: 2.24 )
Ranked among companies with meaningful PFCF only.
MVRBF' s 10-Year PFCF Range
Min: 1.79  Med: 30.91 Max: 1380
Current: 2.24
1.79
1380
POCF 2.21
MVRBF's POCF is ranked higher than
99% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. MVRBF: 2.21 )
Ranked among companies with meaningful POCF only.
MVRBF' s 10-Year POCF Range
Min: 1.76  Med: 32.38 Max: 1061.54
Current: 2.21
1.76
1061.54
EV-to-EBIT 1.20
MVRBF's EV-to-EBIT is ranked higher than
92% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. MVRBF: 1.20 )
Ranked among companies with meaningful EV-to-EBIT only.
MVRBF' s 10-Year EV-to-EBIT Range
Min: -72.1  Med: -9.85 Max: 127.8
Current: 1.2
-72.1
127.8
Shiller P/E 23.45
MVRBF's Shiller P/E is ranked higher than
82% of the 109 Companies
in the Global Biotechnology industry.

( Industry Median: 49.43 vs. MVRBF: 23.45 )
Ranked among companies with meaningful Shiller P/E only.
MVRBF' s 10-Year Shiller P/E Range
Min: 18.7  Med: 31.80 Max: 288.24
Current: 23.45
18.7
288.24
Current Ratio 5.23
MVRBF's Current Ratio is ranked higher than
55% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. MVRBF: 5.23 )
Ranked among companies with meaningful Current Ratio only.
MVRBF' s 10-Year Current Ratio Range
Min: 1.84  Med: 3.79 Max: 11.67
Current: 5.23
1.84
11.67
Quick Ratio 5.13
MVRBF's Quick Ratio is ranked higher than
56% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. MVRBF: 5.13 )
Ranked among companies with meaningful Quick Ratio only.
MVRBF' s 10-Year Quick Ratio Range
Min: 1.83  Med: 3.61 Max: 11.49
Current: 5.13
1.83
11.49
Days Inventory 42.47
MVRBF's Days Inventory is ranked higher than
79% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. MVRBF: 42.47 )
Ranked among companies with meaningful Days Inventory only.
MVRBF' s 10-Year Days Inventory Range
Min: 49.91  Med: 184.31 Max: 480.13
Current: 42.47
49.91
480.13
Days Sales Outstanding 14.43
MVRBF's Days Sales Outstanding is ranked higher than
88% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. MVRBF: 14.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
MVRBF' s 10-Year Days Sales Outstanding Range
Min: 0.15  Med: 35.12 Max: 166.65
Current: 14.43
0.15
166.65

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.22
MVRBF's Price/Net Cash is ranked higher than
83% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. MVRBF: 3.22 )
Ranked among companies with meaningful Price/Net Cash only.
MVRBF' s 10-Year Price/Net Cash Range
Min: 2.57  Med: 13.08 Max: 34.18
Current: 3.22
2.57
34.18
Price/Net Current Asset Value 2.44
MVRBF's Price/Net Current Asset Value is ranked higher than
88% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. MVRBF: 2.44 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MVRBF' s 10-Year Price/Net Current Asset Value Range
Min: 2  Med: 6.74 Max: 15.7
Current: 2.44
2
15.7
Price/Tangible Book 2.36
MVRBF's Price/Tangible Book is ranked higher than
81% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. MVRBF: 2.36 )
Ranked among companies with meaningful Price/Tangible Book only.
MVRBF' s 10-Year Price/Tangible Book Range
Min: 1.96  Med: 5.04 Max: 10.9
Current: 2.36
1.96
10.9
Price/Projected FCF 0.93
MVRBF's Price/Projected FCF is ranked higher than
92% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. MVRBF: 0.93 )
Ranked among companies with meaningful Price/Projected FCF only.
MVRBF' s 10-Year Price/Projected FCF Range
Min: 0.85  Med: 2.27 Max: 23.66
Current: 0.93
0.85
23.66
Price/Median PS Value 0.25
MVRBF's Price/Median PS Value is ranked higher than
94% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. MVRBF: 0.25 )
Ranked among companies with meaningful Price/Median PS Value only.
MVRBF' s 10-Year Price/Median PS Value Range
Min: 0.22  Med: 1.08 Max: 12.83
Current: 0.25
0.22
12.83
Price/Graham Number 0.48
MVRBF's Price/Graham Number is ranked higher than
97% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.52 vs. MVRBF: 0.48 )
Ranked among companies with meaningful Price/Graham Number only.
MVRBF' s 10-Year Price/Graham Number Range
Min: 0.46  Med: 1.40 Max: 3.99
Current: 0.48
0.46
3.99
Earnings Yield (Greenblatt) (%) 83.30
MVRBF's Earnings Yield (Greenblatt) (%) is ranked higher than
98% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. MVRBF: 83.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MVRBF' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.8  Med: 7.20 Max: 105.1
Current: 83.3
0.8
105.1

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0GP7.UK, MVIR B.Sweden, MVR.Germany,
Medivir AB is a pharmaceutical company with an R&D focus on infectious diseases and hepatitis C. The Company works with the entire development chain, from the early research to the finished pharmaceutical product on the market. Its research focuses on infectious diseases and has expertise in the chemistry and biology of the enzyme classes, polymerase and protease. The research portfolio comprises nine pharmaceutical projects, five of which are being conducted in collaboration with partners. Seven of the projects focus on the development of antiviral pharmaceuticals, of which four are conducted in the hepatitis C sphere. The protease inhibitor, simeprevir, has been developed by the Company and Janssen. Positive simeprevir phase III data was reported in December 2012 that will, together with previous phase II data, form the basis for registration applications in the USA, Europe and Japan. The Company markets pharmaceuticals in the Nordic market. The product range comprises approximately 16 prescription pharmaceuticals in different therapeutic spheres. The products include Citodon, Laxabon,Lithionit, Mollipect and Paraflex. Parallel imports of pharmaceuticals to the Swedish market are conducted via the wholly owned subsidiary company, Cross Pharma.
» More Articles for MVRBF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK